Jeremy Wyatt, CEO, Ametris, discusses how operational best practices for integrating wearables into oncology trials center on minimizing patient burden through thoughtful workflow design, careful ...
Charlie Paterson, partner at PA Consulting, explains how mixed signals on FDA risk tolerance are accelerating the ...
TORONTO, April 3, 2025 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming ...
An inter-organizational group of researchers and administrators from Case CCC recently published their work, "Impact of clinical trial design on recruitment of racial and ethnic minorities," in the ...
There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to improve drug development by speeding up clinical trial recruitment. Dubbed Muse, ...
Note: This is the third article of a three-part series. Real-world evidence (RWE) plays a crucial role in supporting the benefits of one drug over another in debates that play out on the boards and ...
Clinical trials often suffer from a lack of participant diversity, resulting in findings that may not fully represent the eventual treated patient population. This issue has improved only modestly in ...
At this year's conference, TransCelerate and representatives from its member companies, including Amgen, Merck, and Pfizer, will participate in seven sessions addressing topics such as data collection ...
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and ...
Eli Lilly believes community-based clinical trials are the wave of the future and is pushing sponsors to embrace the paradigm as a way to boost enrollment and diversity. “In the future, I think we’ll ...
Collaboration reinforces regulatory diligence, nonclinical strategy and clinical trial integrity for novel intranasal concussion therapy ...
Targeted therapies for MASH show progress, with pegozafermin leading in efficacy for fibrosis regression and disease resolution. New research highlights the effectiveness of targeted therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results